TenNor Therapeutics (Suzhou) Company Description

TenNor Therapeutics (Suzhou) Limited engages in discovery, development and commercialization of differentiated therapies for diseases associated with bacterial infections and bacterial metabolism.

The company offers drug production and medical research and experimental development, with a pipeline of products such as Rifasutenizole (oral) for treatment of Helicobacter pylori infection, bacterial vaginosis, difficile infection; TNP-1232 for treatment of Helicobacter pylori infection; Rifasutenizole (injectable) for acute bacterial skin and skin structure infection, prosthetic joint infection, and left ventricular assist device infection; and TNP- 2092 for the treatment of diabetic foot infection.

It also provides TNP-2092 (oral) for the treatment of hepatic encephalopathy and irritable bowel syndrome with diarrhea; TNBm-1, a broad spectrum bifunctional small molecule drug for metabolic disease; and TNBi-2 broad spectrum multi-targeting small molecule drug for Nontuberculous mycobacterial pulmonary disease.

The company was founded in 2012 and is headquartered in Suzhou, China.

TenNor Therapeutics (Suzhou) Limited

Country	China
Founded	2012
Industry	Biotechnology
Sector	Healthcare
Employees	56
CEO	Zhenkun Ma

Contact Details

Address: 218 Xinghu Street Suzhou China
Phone	86 512 8686 1990
Website	tennortherapeutics.com

Stock Details

Ticker Symbol	6872
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100007KG6
SIC Code	2834

Key Executives

Name	Position
Dr. Zhenkun Ma Ph.D.	Founder, Chief Executive Officer, Chairman and GM
Rongping Chen	Vice President of Finance and Board Secretary
Dr. Jie Bi	Chief Business Officer
Yinjiao Yu	Senior Vice President of Regulatory Affairs
Jiahong Ye	Joint Company Secretary
Dr. Guozhu Geng	Vice President of Medical Affairs
Jing Chen	Vice President of Clinical Operation